Management of community-acquired pneumonia because of multidrug-resistant Pseudomonas aeruginosa with Supime: A case study
General Medicine, MCH Udaipur
Case Report
Open Access Research Journal of Multidisciplinary Studies, 2022, 03(01), 038–041.
Article DOI: 10.53022/oarjms.2022.3.1.0024
Publication history:
Received on 10 December 2021; revised on 29 January 2022; accepted on 30 January 2022
Abstract:
Community-acquired pneumonia (CAP), particularly in patients infected with multidrug resistance (MDR) Gram-negative bacilli, is a common and potential serious associated illness leading to considerable morbidity and mortality. Pseudomonas aeruginosa is the second most common pneumonia-causing pathogen, followed by K. pneumonia and S. aureus in India. This resistance is one of the most barriers to bacterial eradication and clinical cure of Pseudomonas infection. This delay in the management of MDR Pseudomonas aeruginosa with antibiotics can lead to increased mortality and morbidity. Here we discuss a case of a CAP caused by pathogen Pseudomonas aeruginosa which was resistant to the first line of antibiotics, piperacillin-tazobactam & cefoperazone sulbactam but sensitive to Supime (cefepime + sulbactam). Supime 3gm BD with 30 minutes of infusions for 7 days was effective in treating and discharging the patient from the hospital. Supime was safe and efficacious to treat hospitalized CAP patient infected with MDR Pseudomonas aeruginosa.
Keywords:
Cefepime + Sulbactam; SUPIME; CAP; MDR; Pseudomonas aeruginosa; CAP
Full text article in PDF:
Copyright information:
Copyright © 2022 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0